- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
Vol. 6, No. 2
Summer 2016
Relevant court decisions highlighted in this issue:
- Spectrum Pharms., Inc. v. Burwell
DC Circuit affirms district court’s summary judgment that the FDA’s ANDA approval for one indication was proper even though branded company enjoyed exclusivity on same product for treatment of another indication. - Intendis GMBH et al. v. Glenmark Pharms. Inc., USA
Affirming district court’s application of the doctrine of equivalents, in part, on the basis of Defendants’ representations to the FDA in their ANDA. - Merck & Cie v. Watson Labs., Inc.
Because a fax containing essential price, delivery, and payment terms to sell the covered product was a premature commercial exploitation of the claimed invention, the asserted claim was invalid under the on-sale bar.
Relevant ANDA updates highlighted in this issue:
- ANDA Approvals
- ANDA Litigation Settlements
- Generic Launches
- New ANDA Cases
Related Professionals
Miles A. Finn, Ph.D.
Counsel
Specific jurisdiction is present in any state where the generic manufacture may sell its ANDA product after FDA approval.
A proposed combination will not render a patent obvious wherein the proposed combination improperly relies on hindsight.
A proposed combination will not render a patent obvious wherein the proposed combination includes changing the core structure of the lead compound.
Plaintiff is awarded injunctive relief following analysis of the eBay factors, but said relief cannot be awarded under § 271(e)(4)(A) because the patents-in-suit issued after Defendants’ ANDAs were filed.
Dismissal of “artificial” § 271(e)(2)(A) claim is warranted when patent holder can bring actual infringement claims against Defendants under § 271(a).
Validity of patent-in-suit upheld in light of art determined to be non-analogous by patent examiner.
Applying the Federal Circuit’s recent decision in Acorda Therapeutics, the court denied defendants’ motion to dismiss on grounds of lack of personal jurisdiction, and also denied defendants’ Rule 12(b)(6) motion because § 271(e)(2) does not explicitly require an entity to sign the ANDA in order for it to be a properly-named defendant.
The asserted claims of the patents-in-suit were not obvious because a POSA would not have been motivated to improve the prior art in line with the inventions claimed.
Affirming district court’s application of the doctrine of equivalents, in part, on the basis of Defendants’ representations to the FDA in their ANDA.
Because a fax containing essential price, delivery, and payment terms to sell the covered product was a premature commercial exploitation of the claimed invention, the asserted claim was invalid under the on-sale bar.
Allowing certification for appeal of patent with severable invention from remaining patents in suit.
Post-hoc expert conclusions were not sufficient to contradict prior-art publications relating to obviousness.
One of Plaintiffs’ patents was valid and infringed while the remaining patents-in-suit were either invalid or not infringed.
DC Circuit affirms district court’s summary judgment that the FDA’s ANDA approval for one indication was proper even though branded company enjoyed exclusivity on same product for treatment of another indication.
A product label that does not encourage direct infringement cannot be the basis for an induced infringement claim.
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.